Detection Immunohistochemical of P21 and P27 expression in Uterine Tumors.

Saad Hasan Mohammed Ali  
Communicable Diseases Research Unit, Baghdad Medical College  
saadhasan@yahoo.com

Basim Shehab Ahmed  
Department of Pathology, College of Medicine, AL-Mustansyria University

Sura Dhafer Dawood  
Department of Microbiology, College of Medicine, AL-Mustansyria University.

Abstract
Background: Several studies assessed gene and protein expression of p21 in endometrial carcinoma (EC), and mention that P21 represents an important participant in EC cell invasion and metastasis, while some researchers indicate that there were no apparent differences in immunostaining for p21. Other studies found that p27 expression significantly reduced in the endometrial carcinoma and inactivation of P27 proteins is a specific feature in the progression of this cancer.

Methodology: This study has used Immunohistochemistry for detection the gene expression of p21 and p27 in tissue specimens from 70 hysterectomized patients diagnosed with malignant uterine tumors (30 cases), non-malignant uterine tumors (25 cases), and 15 cases as control tissue groups.

Results: The results of molecular detection of P21 revealed 12 (40%) in malignant uterine tumors, 8 (32%) in non-malignant uterine tumors, and 5 (33.3%) in control tissue groups. The expression of P27 was low in all groups: 5 (16.7%) in malignant uterine tumors, 6 (24%) in non-malignant uterine tumors, and 2 (13.3%) in control groups.

Conclusions: Decrease in expression of P21 was found mostly in malignant endometrial tumors and this expression occurs could have correlated to the early events of their tumorgenesis. Low expression of P27 in hysterectomized patients mostly appear in non-malignant uterine tumors at the endometrial sites.

Keywords: P21, P27, Uterine Tumors.

Inroduction
Cyclin dependent kinase inhibitors (Cdks) belong to 2 families (1) The inhibitors of Cdk4 (INK4) family (P16\(^{Nk4a}\), P15\(^{Nk4b}\), P18\(^{Nk4c}\), and P19\(^{Nk4d}\)), which inhibit Cdk4 and Cdk6; and (2) Cip/Kip family (P21\(^{Waf/Cip1}\), P27\(^{Hip1}\), and P57\(^{Kip2}\)), which exhibit a broader range of inhibition (Sherr & Roberts, 1999).
P21 protein play important roles in a wide range of cellular process, including cell morphogenesis mortality, survival, cell cycle progression, angiogenesis, cell invasiveness and transformation. Also regulation of cytoskeleton activate C-jan NH2terminal Kinase and extra cellular signal-regulated Kinase, thus influences nuclear signaling (Balasenthil et al, 2004; Siu et al., 2010)

P21 can be regulated via many pathways, include:The tumor suppressor P53, activities P21 expression by binding to its promoter, oncogene MYC, and E-box-binding proteins (Abukhdeir & Park 2009).

The encoding gene (P27Kip1), play role in regulating the progression from G1 to the S-phase. The P27 gene has a DNA sequence similar to other member of the “Cip/Kip” family and similar functional characteristic of being able to bind several different classes of cyclin A, CDK2, and cyclin D-CDK4 complexes (Denicourt & Dowdy, 2004). Authors investigated the clinical significance of p21 expression and its functional roles in Ec (Lu et al.,2013) by promote epithelial hyperplasia through phosphorylation and transactivation of estrogen receptor α-(ER- α) that involved in the pathogenesis of Ec (Di Cristofano & Ellenson, 2007) Also several studies indicated that P21 expression was associated with the progression of Ec and involved in rapid proliferation of cancer cells through the Nf-Kp dependent pathway (Saegusa et al., 2012).

In addition P21 represent an important participant in Ec Cell invasion and metastasis by reorganization through several reported substrates, such as phosphorylates LIM Kinase (Kichna et al, 2010) Moreover, P21 anchorage-independent growth and protects Ec cell from apoptosis induced by TNF- α via caspase-3 activation (Lu et al, 2013).

A study found that p27 expression was present in the proliferative, secretory phases; and In complex hyperplasia with atypia, but significantly reduced in the endometrial carcinoma (Özkara et al 2004). Other study found that inactivation of PTEN/P27Kip proteins is a specific feature in the progression of endometrial carcinoma (Bansal et al, 2009).

This study amid to Evaluation of the expression functionally tumor suppressor genes (i.e. p21and p27) among patients hysterectomized for cancers in their tissues using immunohistochemistry technique.

Materials and Methods
1-Subjects (Patients Tissue Samples)

This retrospective study has enrolled seventy (70) cases represented by 158 selected formalin fixed paraffin embedded uterine tissues blocks were belonging to patients who had undergo hysterectomy. For each patients we were chose blocks from endometrium, myometrium, polyp, fibroid as well as cervix and these blocks were collected from the archives of histopathology laboratories at teaching Laboratories in medical city, Al-Yarmok teaching hospital and private laboratories. These samples were related to the period from 2012 to 2014. The study tissues group comprised thirty cases represented by 66 malignant uterine tumor, 25 non-malignant uterine tumors represented by (62 samples), and 15 control tissues group represented by 30 samples. Immunohistochemical method was used to demonstrate the product of gene expression of P21 and P27 in those uterine tumors tissue and was done according to the manufacturing company (Abcam/UK, Code No. ab80436). This kit used for detection of :Anti-P21 antibody (ab18209) and Anti-P27antibody (ab54563).

Evaluation of IHC results: Proper use of this IHC detection system will given an eintense brown precipitate in positive cell on tissue sections.IHC was given an
intensity grading of the positive signals and scoring of the number of cells contain these signals.

I-P21: for cytoplasmic (P21) expression, the staining intensity was scored in the following manner: 0= negative ,1= weak ,2=moderate ,3= strong .And the staining percentage was scored as: 0=0-5%, 1= 5-25% ,2= 25-75% ,3= 50-75% .And 4= 75-100%.We obtained a composite histoscore by multiplying the value of the 2 parameters percentage epithelium stained x stain intensity: 0-4weak, 5-8moderate, 9-12strong(Lu 2013).

II. P27: For P27 labeling analysis, only nuclear staining was defined as positive and visually counting up to 500 nuclei using high power (x 40 at 8-10 fields), the average of immunopositive nuclei of 10 fields were determine .The finding were recorded as the percentage of immunopositive nuclei, and graded as:0 (negative), 1(<10%), 2(10-50%),3(>50%) .The staining intensity was scored as: 0=negative,1= weak,2=moderate,3= strong (Dellas et al 2009).

Results
1- Detection of IHC staining for P21 in the endometrial tissues among hysterectomized patients:-
The P21 protein staining was captured in endometrial glandular epithelial cell cytoplasm, and the results were as follows:12 cases (40.0%) among malignant uterine tumors,8 cases (32.0%) among non-malignant uterine tumors, and 5 cases (33.3%) among control tissues group. No significant differences (P>0.05) were found among the study groups (Table1).

<table>
<thead>
<tr>
<th>Endometrial-IHC signal results</th>
<th>Malignant uterine tumors</th>
<th>Non-malignant uterine tumors</th>
<th>Control uterine tissues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>%</td>
<td>No</td>
</tr>
<tr>
<td>P21-IHC Signal results</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>12</td>
<td>40.0</td>
<td>8</td>
</tr>
<tr>
<td>Negative</td>
<td>18</td>
<td>60.0</td>
<td>17</td>
</tr>
<tr>
<td>P compared to NT</td>
<td>0.664</td>
<td></td>
<td>0.066</td>
</tr>
<tr>
<td>P compared to Con</td>
<td>0.539</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Significant difference between proportions using Pearson Chi-square test at 0.05 level.

P-p-value,
NT:Non-malignant uterine tumors,
Con:Control uterine tumors

High percentage (33.3%) of score 3 was found among malignant uterine tumors with predominated moderate intensity that constituted (20%), while score 2 was predominated among non-malignant tumors (20%) with predominated moderate intensity was predominated which constituted (20%).No significant differences among the study groups were noticed.(Table 2) (Figure1,2).
Table (2): Distribution of IHC-results of P21 according to their signal scoring & intensity in the endometrial lesions tissue.

<table>
<thead>
<tr>
<th>Pathological Type</th>
<th>IHC Negative results</th>
<th>IHC Positive results</th>
<th>Signal score*</th>
<th>Signal Intensity**</th>
<th>P value x Control uterine tissue</th>
<th>P value x non malignant uterine tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant uterine tumors (30)</td>
<td>18 60%</td>
<td>12 40%</td>
<td>0 2 10 0</td>
<td>L 1 M 6 H 5</td>
<td>0.664</td>
<td>0.539</td>
</tr>
<tr>
<td>Non-malignant uterine tumors (25)</td>
<td>17 68%</td>
<td>8 32%</td>
<td>0 5 2 1 2</td>
<td>L 8 M 8 H 4</td>
<td>0.931</td>
<td></td>
</tr>
<tr>
<td>Control uterine tissues (15)</td>
<td>10 66.66%</td>
<td>5 33.3%</td>
<td>0 2 2 1 2</td>
<td>L 13.3 13.3 6.6 13.3% 20% 3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Significant difference between proportions using Pearson Chi-square test at 0.05 level.

*Score 1(<25%),Score 2(25-50%),Score 3(50-75%),Score 4(>75%)

**L = Low intensity, M = Moderate intensity, H = High Intensity
Figure (1): A-Frequency distribution of IHC-results for P21 according to signal score in the endometrial lesions , B- Frequency distribution of IHC-results for p21 according to signal intensity in the endometrial lesions.
Figure (2): Microphotographs of IHC positive staining for p21 in cell cytoplasm (yellow arrow) of glandular tissue in (A, B) endometrial carcinoma show score 3 with high intensity (400x) (C) endometrial carcinoma show score 2 with low intensity (1000x) (D) non-secretory endometrial gland associated with polyp show score 3 with high intensity (400x) (E) non-secretory endometrial gland show score 2 and moderate intensity (1000x) (F) secretory endometrial gland show score 2 and low intensity (400x).
2- The association between P21 Protein expression, TNM/FIGO staging system and grading of endometrial carcinoma.

Eight (38.1%) cases revealed positive expression of p21 in T1/IB stage lesions, 4 (44%) cases revealed in T2/IIB stage, and 10 (37.0%) of cases had well differentiation grade (figure:3&4)

![Endometrial TNM/FIGO staging](image)

**Figure (3): Distribution of p21 positive expression according to TNM/FIGO staging of the endometrial cancers.**

![Endometrial cancer grading](image)

**Figure (4): Distribution of p21 expression according to the grade of endometrial cancer.**

3- Detection of IHC staining for P27 in the endometrial tissues among hysterectomized patients:-

The P27 protein staining was captured cellular nuclei of the endometrial glandular epithelium tissues. Five cases (16.7%) of malignant uterine tumors showed p27 expression while Six cases (24.0%) of non-malignant uterine tumors and two cases (13.3%) of control groups showed such p27 expression. No significant differences (P>0.05) were found among study groups (Table 3).
Table (3): IHC-results of P27 expression in the endometrial lesions.

<table>
<thead>
<tr>
<th>Endometrial IHC results</th>
<th>Malignant uterine tumors</th>
<th>Non-malignant uterine tumors</th>
<th>Control uterine tissues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>%</td>
<td>No</td>
</tr>
<tr>
<td>P27- IHC signal results</td>
<td>Positive</td>
<td>5</td>
<td>16.7</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>25</td>
<td>83.3</td>
</tr>
<tr>
<td>P compared to NT</td>
<td>0.771</td>
<td>0.624</td>
<td>-</td>
</tr>
<tr>
<td>P compared to CON</td>
<td>0.498</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Significant difference between proportions using Pearson Chi-square test at 0.05 level.

P: p-value.

NT: non-malignant uterine tumors.

CON: Control

In malignant uterine tumor the highest percentage observed (10%) of score 3 with intensity predominated constituted (10%), and in non-malignant tumor (20%) of score 2 with moderate intensity was predominated constituted (20%). There were no differences (P>0.05) according to score and intensity between the study groups (Table 4)(Figure 4,5).

Table (4): Frequency Distribution of IHC-Test for P27 according to Signal Score & Intensity in the endometrial lesions.

<table>
<thead>
<tr>
<th>Pathological types</th>
<th>Negative signaling</th>
<th>Positive signaling</th>
<th>Signal score*</th>
<th>Signal intensity**</th>
<th>P-value x Control uterine tissue</th>
<th>P value x non-malignant uterine tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Score 1</td>
<td>Score 2</td>
<td>Score 3</td>
<td>L</td>
<td>M</td>
<td>H</td>
</tr>
<tr>
<td>Malignant uterine tumors (30)</td>
<td>25</td>
<td>83.3%</td>
<td>5</td>
<td>16.6%</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Non-malignant uterine tumors (25)</td>
<td>19</td>
<td>76%</td>
<td>6</td>
<td>24%</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Control uterine tumors 15</td>
<td>13</td>
<td>86.6%</td>
<td>2</td>
<td>13.33%</td>
<td>1</td>
<td>6.66%</td>
</tr>
</tbody>
</table>

Significant difference between proportions using Pearson Chi-square test at 0.05 level.

*Score 1(<10%), score 2 (10-50%), score 3(>50%)

**L = Low intensity, M = Moderate intensity, H = High Intensity
A-

![Graph A: Frequency Distribution of IHC results for P27 according to Signal Score in the endometrial lesions.]

B-

![Graph B: Frequency Distribution of IHC results for P27 according to Signal intensity in the endometrial lesions.]

Figure (4): A- Frequency Distribution of IHC-results for P27 according to Signal Score in the endometrial lesions, B- Frequency Distribution of IHC-results for P27 according to Signal intensity in the endometrial lesions.
Figure(5): Microphotographs of IHC positive staining for p27 in cell nuclei(yellow arrow) of the glandular tissues in (A,B) Endometrial carcinoma shows score 3 with high intensity (C) Endometrial carcinoma shows score 2 with low intensity(D) Non secretory endometrial gland associated with fiboid shows score3 with low intensity (E)Non secretory endometrial gland show score 3 and moderate intensity (F)Secretory endometrial gland show score 2 and high intensity (1000x).
4- The association between P27 protein expression and TNM/FIGO system and grading of endometrial carcinoma

Three cases (14.3%) with T1/B1 revealed P27 gene expression and two cases (22.2%) with T2/BII while four cases (14.3%) of endometrial carcinoma that had well differentiation expressed such P27 protein (Figure: 6, 7).

Figure (6): Distribution of p27 positive expression according to TNM/FIGO staging of the endometrial carcinoma.

Figure (7): Distribution of p27 expression according to the grade of endometrial cancer.

Discussion

1- Detection of P21 expression in endometrial lesions (Table 1&2)(Figure 1&2) 
In the present study, a decreased expression of P21 was detected by IHC technique in cytoplasm of epithelial cells and mostly has been revealed in the malignant uterine tumors as compared to the other two groups with no significant associations among the study groups. Our findings are in agreement with the results of (Palazzo et al, 1997, Palazzo et al, 2000, Semczu et al, 2003, Ignatov, 2008, and Felix et al, 2015). They have revealed that a decreased expression of P21 has no independent influence on the endometrial carcinoma and they also reported that P21 have consistent
relationship with tumor characteristics among women with endometrial carcinoma where they are supported also by the studies done in China by Lu et al., 2013 and in Egypt by Abdelmonem & Abdelmajed, 2008 were they concluded that P21 has involved in activation cell growth of endometrial carcinoma and could be useful marker for prognosis.

The expression pattern and function of P21 in endometrial carcinoma remain unknown. Several studies indicated that inactivation of inhibitory factors (CDK inhibitors or pRb) have potential to disturb the cell cycle that lead to an initial uncontrolled cell proliferation (Flexi et al., 2015). Also aberrant expression of the CDK inhibitors has been frequently characterized in endometrial carcinoma cases (Milde-Langosch & Riethdorf, 2003) and decreased expression of P21 is associated with promotion of tumor formation and poor prognosis in many types of cancer (Abukhdeir & Park, 2009). Elbendary et al., 1996 and Migaldi et al., 2000 noted a correlation between P53 mutation and absent or reduce P21 expression consistent with the hypothesis that P53 is an important regulator of P21 expression. Others mention that failure of mutant P53 protein to transactivate P21 may lead to uncontrolled proliferation since P21 molecule was identified as a mediator of P53-dependent growth suppression and wild type P53 induces the expression of P21, which blocks the progression of cell cycle at G1/S transition by inhibitory (CDKs) (Scian et al., 2004). Other study mention that E7 oncoprotein of HPV can contarget the P21 for degradation during carcinogenesis (Tagle et al., 2014).

Also the present study has revealed a low percentage of expressed P21 in the early FIGO stage (T2/IIB) (44.4%) and (T1/IB) (38.1%) and in well differentiation grade (33.3%) (Figures 3&4) make a suggestion that low expression of P21 could indicated for a initial tumor event but not progression of the carcinogenesis and has no association with clinicopathological parameters (type, stage and grade) and as supposed by (Flexi et al., 2015).

II- Detection of P27 expression in endometrial sites among hysterectomized patients (Table 3,4)(Figure 5,6):

The results in the present study revealed low expression of P27 in the tissues in all study groups and these results are in agreement with several studies that found a loss or absence in the expression of p27 an important step in promoting the tumor growth(Watanabe et al., 2002, Özkara et al, 2004).

Our study has revealed a low expression of P27 in the endometrial carcinoma tissue group which was already observed in well differentiated malignant cases (13.33%) and in those with T1b/1B stage (10%) (Figure 7 & 8). These findings have suggested that decreased the expression of P27 may be an early event in the initiation of endometrial carcinoma, but not associated with prognostic factor (stage, grade and type) and we in agreement with (Nycum et al., 2001) study who suggested that expression of P27 was not associated with prognostic factor such as FIGO stage.

Several studies suggested that one of the mechanisms that leads to low or absent of P27 expression is up-regulation or disordered of SKP2 (S-phase kinase interacting protein-2) the P27-ligase, which leads to degradation by ubiquitin-proteasome pathway(Watanabe et al., 2002). Other possible mechanism of the abnormality in P27 expression could be gene mutation, excessive amount of the complex cyclin E/CDK, or consumption of P27 may be a trapped by other factors such as cyclin D1 and D3(Watanabe et al., 2002).

The current study has observed that P27 expression in the nuclei of glandular cells in some cases of non-malignant tumors and in control tissues that are
represented by secretory and late secretory endometrial glands. This finding is in agreement with suggestions of several other studies (Lahav-Barat et al., 2004, Shiozawa et al., 2004). Expression of P27 could probably a result of cellular response to the hormones and the regulation of P27 expression may be induced by the progesterone suggested that a markedly p27 expression induced by progesterone in the secretory phase might develop cell growth arrest by inhibiting the cyclin E/cdk2 complex and it was a result of a persistent accumulation of p27 due to a prolonged half-life by progesterone-mediated impaired proteolytic activity (Watanabe et al., 2002).

References
Lahav-Barat S, Ben-Izhak O, Sabo E, Ben-Eliezer S, Lavie O, Ishai D, Ciechanover A and Dirnfeld M: Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not


Özkara SK & Corakci: A Significantly Decreased P27 Expression In Endometrial Carcinoma Compared to Complex Hyperplasia with Atypia (correlation with p53 expression).


PATHOLOGY ONCOLOGY RESEARCH, 2004; Vol 10, No 2.


